behavior of the disaccharidases in our experimental model remains a moot point.
The absence of morpohologic changes by light microscopy in our model probably is due to the short time which elapsed after challenge. Using a similar model, Perdue et al. (unpublished data) found that while morphologic changes could not be identified 1% h after challenge, after 4 h, edema and shredding of enterocytes could be demonstrated. characteristic organic aciduria that distinguishes this disorder from Reye syndrome and other masqueraders characterized by dicarboxylic aciduria. The key metabolites, suberylglycine and hexanoylglycine, are excreted in high concentration only when the patients are acutely ill. More significantly, using novel techniques in mass spectrometry, the medium-chain defect is shown to be characterized by excretion of specific medium-chain acylcarnitines, mostly octanoylcarnitine, without significant excretion of a normal metabolite, acetylcarnitine, in four patients with documented enzyme deficiency. Similar studies on the urine of two patients reported with Reye-like syndromes of unidentified etiology have suggested the retrospective diagnosis of medium-chain acyl-coA dehydrogenase deficiency. Administration of L-carnitine to medium-chain acyl-coA dehydrogenase deficiency patients resulted in the enhanced excretion of medium-chain acylcarnitines. Octanoylcarnitine is prominent in the urine both prior to and following L-carnitine supplementation. The detection of this metabolite as liberated octanoic acid, following ion-exchange chromatographic purification and mild alkaline hydrolysis, provides a straightforward diagnostic procedure for recognition of this disorder without subjecting patients to the significant risk of fasting. In view of the carnitine deficiency and the demonstrated ability to excrete the toxic mediumchain acyl-coA compounds as acylcarnitines, a combined therapy of reduced dietary fat and L-carnitine supplementation (25 mg/kg/6 h) has been devised and applied with positive outcome in two new cases. (Pediatr Res 19: 459-466,1985) Abbreviations MCAD, medium-chain acyl-coA dehydrogenase deficiency coA, coenzyme A GC/MS, gas chromatography-mass spectrometry FAB, fast atom bombardment B, magnetic field E, electric field Several inherited metabolic diseases including propionic acidemia, methylmalonic aciduria, isovaleric acidemia, hydroxymethylglutaric aciduria, multiple acyl-coA dehydrogenase deficiency, and more recently, MCAD are occasionally confused with Reye syndrome owing to similar clinical presentation. During acute illness, these disorders frequently have an associated dicarboxylic aciduria, with low free carnitine and relatively increased short-chain acylcarnitines in both urine and plasma. Although dicarboxylic aciduria is a frequent concomitant of reduced carnitine, there is growing evidence that the acylcarnitines excreted in these disorders are derived from metabolites characteristic of the enzyme deficiency (1) .
MCAD is an intramitochondrial defect in fatty acid oxidation associated with reduced plasma and tissue carnitine levels (2) . This disorder presents with life-threatening hypoglycemia and coma reminiscent of Reye syndrome. Deaths have been reported in affected siblings whose postmortem findings included fat accumulation in hepatocytes, brain swelling, and uncal herniation (2) . Recently developed assays for the dehydrogenase enzyme activity summarized by Gregerson (3) have confirmed MCAD in approximately 10 cases (2, (4) (5) (6) (7) (8) . Numerous other cases have been reported which are very similar in clinical description but without enzymatic verification, where MCAD is indicated by the excretion of metabolites consistent with the disorder (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Such patients, presenting with recurrent hypoglycemia of unknown etiology, are frequently subjected to a diagnostic fast to assess the integrity of gluconeogenesis during fasting stress. In some instances this can be disastrous, resulting in death (9) or coma responding to glucose infusion (19) . It is not yet clear whether glucose deficiency or an excess of other metabolites is responsible for clinical deterioration in this disease. Similarly, there has been no explanation for the abnormality in carnitine metabolism associated with this disorder.
This report describes two additional families with three affected children. Studies on these children are compared with results obtained from patients with Reye syndrome, and patients with dicarboxylic aciduria secondary to dietary load. In addition, urine samples from the patients reported earlier by Stanley et al. (2) , Gregerson et al. (9) , and by Chalmers et al. (1 1) were studied for comparison.
The studies describe the distinguishing organic acid metabolites in these disorders in addition to the characteristic acylcarnitines which were identified using novel mass spectrometric techniques. The data indicate that MCAD can be readily recognized by metabolite analysis without subjecting patients to the risk of diagnostic fasting and may be treated effectively using supplemental L-carnitine.
MATERIALS AND METHODS
Octanoylcarnitine and hexanoylcarnitine were synthesized, purified, and characterized by methods previously described (20, 21) . Hexanoylglycine and suberylglycine were synthesized by conjugation of the corresponding acid chloride with glycine under basic conditions. Water was deionized and distilled; all solvents and chemicals were of reagent grade.
Plasma and urinary free carnitine, short-chain acylcarnitines, and long-chain acylcarnitines were determined by the radioenzymatic assay utilizing ['4C-l]acetyl-coA and carnitine acetyltransferase as described by Brass and Hoppel (22) .
To obtain organic acid profiles, urine samples (2 ml) were treated with ethoxyamine hydrochloride (0.4 g, Fisher Scientific, Raleigh, NC) acidified to pH 1, saturated with sodium chloride, then successively extracted with ether (3 x 2 ml) and ethyl acetate (3 x 2 ml). The combined extracts were evaporated under a stream of nitrogen, derivatized with bis(trimethylsily1) trifluroacetamide (Sigma Chemical Co., St. Louis, MO), and analyzed by GC/MS. The samples (2 p1) were injected (temperature 250" C, split ratio 150) onto a 30 m x 0.25 mm id fused silica capillary GC column (DB-1, J & W Scientific, Rancho Cordova, CA) directly coupled to the ion source of the HP-5985 gas chromatograph-mass spectrometer (Hewlett-Packard, Inc., Palo Alto, CA). After an initial hold at 120" C for 5 min, the oven temperature was programmed at 8" C/min to 280" C. The MS was scanned repetitively over the mass range 500-50 at 800 daltons/ s and all data stored on cartridge disks compatible with the HP-7920 disk drive. The ion source was operated in EI mode at 200" C with an electron energy of 70 eV.
For the identification of acylcarnitines, each of the urine samples (0.5-2.0 ml) was acidified and passed through a column (30 mm x 4 mm) of Dowex-50 ion-exchange resin (Bio-Rad Laboratories, Richmond, CA). After washing with 0.01 N HCl (15 ml) and water (15 ml), the acylcarnitines were eluted with 1 N NH40H in ethanollwater (1:4) and the mixture lyophilized. The residue was treated with urease (1 unit, Sigma Chemical Company) in water (1.0 ml) at 37" C for 0.5 h, then lyophilized again. The residue was then dissolved in 0.01 N HC1 (0.2 ml) prior to analysis by fast atom bombardment-MS and constant B/E ratio linked scanning. These analyses were performed on 2-5 pl of sample using a VG-7070HS/ll-250 (VG-Instruments, Inc., Stamford, CT) mass spectrometer/datasystem combination as described earlier (21) . The remaining sample was hydrolyzed (0.2 N KOH, 37" C, 1 h), acidified to pH 2, and extracted with ether (3 x 1.0 ml). The combined extract was treated with excess ethereal diazomethane and carefully concentrated under N2 to a final volume of about 0.1 ml, then analyzed by capillary GC/ MS.
CASE REPORTS
Patients with Reye syndrome. Three patients presenting with Reye syndrome in stage I1 are included in this analysis. These same patients were studied again 8-12 months following that episode and are considered control patients at that time.
Patients on ketogenic diet. Three additional patients with dicarboxylic aciduria due to excessive medium-chain triglyceride intake in the diet are also included for study of the specificity of urinary organic acid and acylcarnitine analyses compared to children with MCAD deficiency or Reye syndrome.
Patient R-I. A female patient presented to Duke Medical Center at 13 months of age, 1 wk following hospitalization for suspected Reye syndrome. She had a respiratory infection with fever which progressed to lethargy and unresponsiveness following a high fat meal. She had two generalized seizures associated with a plasma glucose of 22 mg/dl, CSF glucose 7, ammonia 1 12 pgldl, normal sodium and potassium, C 0 2 17, SGOT 224 IU/ L. CT scan on admission suggested petechial hemorrhages in the right fronto-parietal area. Physical examination revealed a febrile, flaccid, unresponsive female with hepatomegaly (5 cm), but who appeared normal in weight and height. Developmental history was normal. Her neurological exam was improved by 48 h and she was awake and responsive by the 6th hospital day. Analysis of urinary organic acids during this interval revealed dicarboxylic aciduria, 5-hydroxyhexanoate, hexanoylglycine, suberylglycine, and octanoate. Plasma and urinary carnitine data are presented in Table 1 as baseline values. The association of the organic aciduria with low plasma and urine free carnitine prompted RESULTS 
* Carnitine expressed as nmol/ml of plasma and nmol/mg creatinine in urine. SC-acyl, short-and medium-chain acylcarnitines.
t Specimens collected at the peak of acylcarnitine excretion, usually 6-8 h after the load.
$ Acyl, combined acylcarnitines. Approximately 63% of these values for the patients R-1 and K is accounted for by octanoylcarnitine (see text).
reduction of dietary fat (<20% total kcallday) and L-carnitine supplementation (25 mg/kg/6 h). This regimen resulted in an improved urinary organic acid profile, restoration of normal free carnitine levels, reduced hepatic enlargement, and normal serum transaminases.
Her course since discharge has been complicated by complex partial seizures without hypoglycemia or organic aciduria but controlled by phenobarbital. At age 25/~2 yr, she is developmentally and intellectually normal. Her parents are unrelated and normal (carnitine status and GC-MS of organic acids).
Patient R-2. This male sibling of patient R-1 was a normal product of a term pregnancy. He had no prior illness when at 7 months of age he was found dead in his crib in the early morning hours. Autopsy revealed marked fatty change of the liver, diffuse cerebral edema, marked acute interstitial pneumonia, and myocarditis apparently due to Coxsackie B-5 viral infection. Biological fluids and tissue were not available for study.
Patient K. The patient was well until 7 months of age when she developed bilateral serous otitis media. After 2 days of therapy, she was found unconscious, limp, and had jerking eye movements. She was hospitalized and found to have a blood glucose level of 4 mg/dl. At 11 months of age, she was again found limp, clammy, and unconscious. Blood glucose at that time was 30 mgldl. She has had seven additional episodes of hypoglycemia. She was admitted to Duke Medical Center where urinary organic acid analysis by GC-MS revealed the same metabolites as in patient R-1. The plasma and urinary carnitine concentrations are given in Table 1 (baseline data). Dietary fat was restricted and she improved markedly. She has since been treated with L-carnitine 25 mg/kg/6 h and has experienced no further hypoglycemic episodes or hospitalization. Her parents are unrelated and there is no family history of hypoglycemia, coma, or death in childhood.
Enzyme assays. Fibroblast cultures from patients R-1 and K were assayed for long-, medium-, and short-chain acyl-coA dehydrogenase activity, using palmityl-coA, octanoyl-coA, and butyryl-coA respectively as the substrates. The assays were performed at the Children's Hospital, Philadelphia by Dr. P. Coates, using a method (23) 
Organic acid analyses. Urinary organic acid analysis by GC-MS revealed specific differences between Reye syndrome and MCAD. In Figure 1 A, Note: these analyses were performed at different times and under slightly different conditions, hence the elution times for each component are not exactly the same. Components were identified by matching GC retention and mass spectrum with those of authentic standards, except for unsaturated dicarboxylic acids for which standards were unavailable.
admission urine sample from a child with stage I1 Reye syndrome is shown. The major features include dicarboxylic aciduria (adipate, suberate, sebacate), a small amount of 5-hydroxyhexanoate, aspirin metabolites (salicylate, gentisate, and salicylurate), significant ketosis (3-OH butyrate, acetoacetate), and greatly increased lactate. The only glycine conjugates present are hippurate (benzoylglycine) and salicylurate (salicylglycine).
Organic acids in three patients with dicarboxylic aciduria secondary to increased medium chain triglyceride intake were also studied by GC-MS. A typical profile is presented in Figure  1 B. The usual dicarboxylic acids, adipate, suberate, and sebacate were noted along with 5-hydroxy hexanoate. No acylglycines other than hippurate or unsaturated dicarboxylic acids were noted. Figure 1 C shows the organic acid profile of patient R-1 during the Reye-like episode. The major distinguishing features seen in this example of MCAD are as follows: dicarboxylic aciduria including saturated and unsaturated medium-chain dicarboxylic acids, 5-hydroxyhexanoate, hexanoylglycine, suberylglycine, and low ketones. When this patient was well, only a small amount of hexanoylglycine was noted (Fig. 1 D) in an otherwise normal profile.
A similar analysis was performed on samples from patient TB previously reported as having a Reye-like illness in which 5-OH hexanoate was first identified by Chalmers et al. (1 1) . Adipic, suberic, sebacic, octenedioic, decenedioic, and octanoic acids were also reported. The new studies of this patient's urine clearly reveal significant peaks of both hexanoylglycine and suberylglycine, standards of which were not available to Chalmers et al. In Figure 2 , the mass spectra of the TMS derivatives of hexanoylglycine and suberylglycine and of hexenedioic, octenedioic, and decenedioic acids (dehydro-adipic, -suberic, -sebacic acids) are presented. These are useful in the recognition of the medium-chain defect. To our knowledge, only the mass spectrum of suberylglycine-TMS derivative has been previously published (25, 26) .
Carnitine supplementation. The two patients with MCAD and three control patients were each given an oral L-carnitine load of 100 mg/kg. Prior to carnitine administration, the plasma and m/z- urinary free carnitine levels in patient R-1 were significantly lower than the control values (Table I) . Patient K had only a slight decrease in plasma free carnitine and normal urinary free carnitine, but was already on a diet restricted in fat, in contrast to patient R-1.
Following carnitine supplementation, plasma and urinary levels of all carnitine fractions increased in all patients. The maximum excretion occurred approximately 6 h after the bolus was administered. Plasma free carnitine was normalized in the MCAD patients and, as expected, increased in the controls. The increase in short-chain acylcarnitines in plasma and urine was much greater in the controls than in the patients. Similarly, the concentration of urinary free carnitine was much greater in the controls than the patients, even though each received the same oral dose. Although the proportion of acylcarnitines excreted relative to total carnitine (25-29%) was similar in all cases, studies by MS revealed major differences in the composition of the acylcarnitine fraction (see below).
Identification of the acylcarnitines. The combined techniques of FAB-MS and constant B/E ratio linked scanning were employed to investigate the composition of the acylcarnitine fraction. As shown in Figure 3A , the FAB mass spectrum of a postcarnitine urine sample from patient R-1 revealed major ions at m/z 260, 286, 288, and 314. These four ions are consistent with the expected masses of protonated molecular ions (MH+) for hexanoylcarnitine, octenoylcarnitine, octanoylcarnitine, and decenoylcarnitine. Of particular note is the absence of the m/z 204 ion, the MH+ ion of acetylcarnitine, which is the predominant acylcarnitine observed in normal individuals. The m/z 288 ion was always seen in the purified urine of the patients with MCAD even prior to carnitine therapy and when on dietary fat restriction. At those times, the organic acid profiles were relatively unremarkable (Fig. ID) . Further evidence that the m/z 288, 314, and 260 ions represent acylcarnitines is provided by their fragmentation patterns, obtained by constant B/E ratio linked scanning, in which the characteristic loss of 59 daltons occurs (Fig. 3 B-D) . This loss reflects elimination of the trimethylamine, (CH3I3N, fragment of the carnitine molecule (21) . The fragmentation pattern of the synthetic octanoylcarnitine (MH+) ion (Fig. 3E) is indistinguishable from that of the m/z 288 ion in the patient's urine (Fig. 3B) . Octanoylcarnitine was detectable by this technique in samples originally containing as little as 30-50 nmol (total) acylcarnitine, as determined by radioenzymatic assay. It is noteworthy that the pattern of the acylcarnitine signals, characterized by the relative abundances of the four major ions, was essentially similar in all the MCAD urine extracts, before and after L-carnitine supplementation. In addition, when the acylcarnitine concentration exceeded 300 nmol/ml, which it did from about 2-6 h following a 100 mg/kg bolus of carnitine, the acylcarnitine signals were detectable by direct FAB-MS analysis of the urine without purification.
Further confirmation of these acylcarnitine structures was obtained by mild alkaline hydrolysis of the purified acylcarnitine fraction, followed by GC/MS analysis of the liberated acids as their methyl esters. This analysis identified hexanoic, octenoic, octanoic (mainly), and decenoic acids in approximately the same relative concentration as indicated by the (MH+) ion ratios in the expanded FAB-MS spectrum (Fig. 4) . These liberated acids were not seen in the ether extract of the purified acylcarnitine fraction before hydrolysis, or in hydrolysates from the control urines. Acylglycines were completely ineit to the hydrolysis conditions. By adding to selected purified urine samples a known amount of n-valeric acid, then carrying out base hydrolysis (GC/ MS as described), the approximate relative molar concentrations of the liberated hexanoic and octanoic acids were calculated. The sum of these values, after correction for losses during the purification, was in good agreement with the total acylcarnitine concentration determined radioenzymatically for each urine sample. From the relative abundances of these GC peaks, the proportion of each acylcarnitine in the urine samples of patients R-1 and K (Table 1 ) was estimated as follows: hexanoylcarnitine-l3%, octenoylcarnitine-1 1 %, octanoylcarnitine-63%, decenoylcarnitine-13%. These data support the application of ion-exchange column purification, mild alkaline hydrolysis, and GC as a valid procedure for acylcarnitine analysis, at least in the recognition of metabolic disorders such as MCAD. Bieber and Lewin (27) suggested a similar protocol, but have been unable to offer verification in the absence of a specific method for the intact acylcarnitines.
The mass spectra of the liberated unsaturated acid methyl esters were inconsistent with the double-bond location at position 2 (large m/z 74 to 87 ratio, absence of m/z 131). Thus, the occurrence of octenoylcarnitine and decenoylcarnitine is not due to a problem associated with the enoyl hydratase of @-oxidation.
MCAD URINE ( F A B )
288 (OCTANOYLCARNITINE) BASE HYDROLYSATE ( G C / M S ) Components were identified and quantified as methyl esters. N-valeric acid was added to the hydrolysate as an internal standard. The major component, octanoic acid, accounted for 63% of the total liberated acid fraction. Acetic acid is not detectable by this method. Note: the m/z 302 ion does not appear to represent an acylcarnitine either by B/E linked scanning or base hydrolysis.
More likely, their origin is unsaturated long-chain fatty acid from triglycerides.
Similar analyses for identification of acylcarnitines have been canied out on urine samples from patients M-1 and B-2 reported by Stanley et al. (2) , patient TB reported by Chalmers et al. (1 I) , and patient JG reported by Gregersen et al. (9) as well as patients with Reye syndrome and dicarboxylic aciduria secondary to nutritional factors. FAB-MS confirms that the medium-chain acylcarnitines, with octanoylcarnitine being most prominent, are characteristic of the medium-chain defect and include patients TB and JG. These acylcarnitine species have not been observed in any other disorder, including the long-chain acyl-coA dehydrogenase deficiency (two patients; Roe CR, Millington DS, unpublished results). Instead, mostly acetylcarnitine was obsewed. Long-chain acylcarnitines were tentatively identified in one of the long-chain acyl-coA dehydrogenase deficiency patients after a carnitine load, but it is stressed that these data are preliminary and more research is required before definitive profiles can be published. The lack of octanoylcarnitine was, however, established conclusively. The likelihood of a defect in the medium chain acyl Co-A dehydrogenase was reported by Kolvraa et al. (4) . Unfortunately, fibroblasts were not available for study from patient JG and the enzyme defect in this patient and TB has not been identified directly. Recently, Stanley et al. (2) reported three children in two families with similar clinical course and successfully identified a deficiency of the medium-chain acyl-coA dehydrogenase in each of them. The availability of new assays for this enzyme activity has enabled verification of several more cases (5-8).
The two new patients (R-1 and K) studied in the present investigation were shown to have deficiency of the medium chain acyl-coA dehydrogenase. Additionally, samples of urine from patients M-1, B-2, TB, and JG were made available for further evaluation. The organic acid analyses essentially confirmed previous findings of dicarboxylic aciduria (adipate, suberate, sebacate) and revealed the presence of 5-hydroxyhexanoate, hexanoylglycine, and suberylglycine in each. Suberylglycine was clearly present in patient TB which was first examined prior to the availability of the mass spectrum of this compound. The organic aciduria varies with the clinical state. When the patient is ill, it is characteristic and believed to be unique to this disorder (Fig. lC) , since other dicarboxylic aciduria profiles are not associated with hexanoylglycine or suberylglycine. The abnormal metabolites disappear when the patient is under good control.
These findings are entirely consistent with those of Divry et al. (17) and Duran et al. (16) . Furthermore, dicarboxylic aciduria is not in itself an index of MCAD, as implied in some earlier reports (3, 6, 14) , rather it represents the general condition of defective or compromised mitochondrial poxidation. This condition frequently results from enhanced lipolysis, as many occur in response to infection, when there is an underlying insuff~ciency of carnitine. Patients with inherited disorders of fat and amino acid metabolism are generally chronically deficient in carnitine (28) . The condition can also arise, as documented here and elsewhere (1 7), during periods of excessive dietary medium-chain triglyceride intake.
The rather specific association of these acylglycines with the MCAD deficiency would suggest that the patient recently reported by Rocchiccioli et al. (25) who had a "Reye-like" illness with hypoglycemia and suberylglycinuria probably also represents this disorder.
Stanley et al. (2) reported decreased plasma free carnitine and increased short-chain acylcarnitines in their patients. They also demonstrated a significant reduction in total carnitine in liver and muscle tissue. The new patients in our study had reduced plasma free carnitine and the ratio of urinary acylcarnitines to urinary free carnitine was significantly elevated in patient R-1 but not in patient K, who was already on dietary fat restriction. These patients responded to carnitine supplementation by increased output of acylcarnitine but not as impressively as the controls. The ratio of urinary acylcarnitine to total carnitine excretion was in the control range of about 25-30%. This is very different from patients with propionic acidemia (29) , methylmalonic aciduria (30) , and isovaleric acidemia (31) where this ratio ranges from 7 1-85%.
FAB-MS has revealed that the profile of acylcarnitines excreted in MCAD is unique. The controls, the patients with Reye syndrome and those with diet-induced dicarboxylic aciduria excreted predominantly acetylcarnitine. Acetylcarnitine was not, how-ever, seen in patients with MCAD. Instead, our patient's samples and those of Stanley, Chalmers, and Gregersen were characterized by the unequivocal identification of octanoylcarnitine, hexanoylcarnitine, octenoylcarnitine, and decenoylcarnitine. Octanoylcarnitine was clearly present in the largest amount (about 63% of the total) and the relative abundances of the other acylcarnitines were remarkably similar in all the samples. Duran et al. (15, 16) have previously identified octanoylcarnitine in MCAD patients' urine using a less specific paper chromatographic technique. Interestingly, Gregerson et al. (14) observed significantly higher levels of octanoate in the hydrolyzed urine of their patient than could be accounted for by the amounts of the free acids and its glycine conjugate before hydrolysis. This discrepancy has subsequently been ascribed to the carnitine conjugate (1 6, 17) , which is now confirmed.
Octanoylcarnitine was always present in the urine of our MCAD patients, regardless of the clinical state. Therefore, even when the organic aciduria is not expressed dramatically, MCAD can be distinguished from Reye syndrome and other dicarboxylic acidurias including the long chain acyl-coA dehydrogenase deficiency. This is particularly important for diagnostic evaluation, since fasting a patient, with the risk of life-threatening consequences, now seems unnecessary. Identification of the acylcarnitine will readily identify the defect. Furthermore, administration of L-carnitine as a bolus enhances the excretion of these diagnostic acylcarnitines, which can now be recognized by a simplified procedure employing mild alkaline hydrolysis and gas chromatographic analysis of the liberated acids, a technique available to most clinical service laboratories.
The clinical similarity between the MCAD and Reye syndrome was recognized before the identification of the enzyme defect, evidenced by the descriptive phrase "Reye-like'' syndrome. Where autopsy information is available on children dying suddenly with this defect, cerebral edema and fat accumulation in the liver are observed, as in Reye syndrome. Mamunes et al. (32) have reported elevated plasma octanoate levels in children with Reye syndrome. From this initial observation, the octanoate infusion animal model of Reye syndrome evolved (33) and persists despite the fact that more recent studies have failed to detect octanoate in plasma from Reye syndrome patients (34) . However, this animal model appears to be more specific for human MCAD. Recent studies by Kim et al. (35) demonstrate that octanoate produces extensive ultrastructural and functional damage to the mitochondria of the choroid plexus. Neither octanoylcarnitine nor L-carnitine produce such ultrastructural abnormalities in this tissue. These observations may help to explain the findings of Waber et al. (19) who demonstrated that a child with MCAD was able to tolerate fasting without the usual response of hypoglycemia and depressed sensorium following carnitine supplementation.
Our studies demonstrate that the carnitine octanoyltransferase is operational in this disease and can be successfully used to convert medium-chain acyl-coA compounds to nontoxic acylcarnitines. These compounds are then excreted in the urine releasing free coA for other metabolic reactions.
In summary, MCAD is a Reye-like illness in clinical presentation, further characterized by suberylglycinuria, octanoylcarnitinuria, and carnitine deficiency. The evidence also suggests mitochondrial accumulation of toxic medium-chain acyl-coA compounds. L-Carnitine administration, previously shown to protect from hypoglycemia during fasting, enhances the excretion of the acyl-coA compounds as specific medium-chain acylcarnitines. We therefore recommend that treatment of MCAD consist of a combination of reduced dietary fat intake and Lcarnitine supplementation.
